Ledger.Open graph →
SEC Form D · filed August 12, 2025

Kestrel Therapeutics Inc

Offering
$10.0M
Sold
$5.0M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
Boston, MA
Type
—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (18)

David Barker · Fern Park, FLExec · DirectorDenis G. Patrick · Boston, MADirectorFrank G. Haluska · Boston, MAExec · DirectorFrank G. Haluska · Boston, MAExec · DirectorNicholas G. Saccomano · Boston, MADirectorDenis G. Patrick · Boston, MADirectorChad L. Mcghee · Fern Park, FLDirectorBarbara G. Sosnowski · Boston, MADirectorFred D. Clark · Fern Park, FLDirectorRichard Ungaro · Fern Park, FLDirectorNicholas G. Saccomano · Boston, MADirectorHarrison L. Hodges · Fern Park, FLDirectorOmar G. Khalil · Boston, MADirectorAndrew G. Phillips · Boston, MADirectorAndrew G. Phillips · Boston, MADirectorBarbara G. Sosnowski · Boston, MADirectorAaron Dillon · NEW YORK, NYDirectorOmar G. Khalil · Boston, MADirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗